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Traditionally, BRCA genetic testing has been undertaken to identify patients and family 
members at future risk of developing cancer and patients have been referred for testing 
based on family history. However, the now recognised risk of ovarian carcinoma (OC) 
patients, even those with no known family history, harbouring a mutation in BRCA1/2, 
together with the first poly adenosine diphosphate [ADP] ribose polymerase inhibitor (PARPi; 
olaparib [Lynparza™]) being licensed for the treatment of BRCA-mutated OC, has led to 
reconsideration of referral criteria for OC patients. Provided here is a review of the existing 
data and guidelines in the European Union, relating to recommendations, as well as 
considerations, for the referral of OC patients for BRCA genetic testing. Based on this review 
of newly updated guidance and up-to-date evidence, the following is recommended: all 
patients with invasive epithelial OC (excluding borderline or mucinous), including those with 
fallopian tube and peritoneal cancers, should be considered as candidates for referral for 
BRCA genetic testing, irrespective of age; genetic testing should ideally be offered at 
diagnosis, although patients can be referred at any stage; retrospective testing should be 
offered to patients in long-term follow-up because of the implications for family members and 
individual future breast cancer risk; and germline BRCA testing of a blood/saliva sample 
should initially be conducted and, if negative, tumour tissue should be tested (to identify non-
germline [somatic] BRCA PARPi therapy candidates). 
 
 
Highlights (max 85 characters, including spaces, per bullet point): 
 Offer BRCA genetic testing to all invasive epithelial OC patients (excluding borderline 
and mucinous cancers) 
 Testing should be irrespective of age 
 Ideally offer testing at diagnosis, although patients can be referred at any stage 
 Retrospective testing should be offered to patients in long-term follow-up 
 Tumour testing should be considered in non-germline-mutated patients 
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Ovarian cancer (OC) is the fifth most common cancer in European women; estimated 65,500 
cases and 42,700 deaths annually [1]. Germline mutations in BRCA1 and BRCA2 (tumour 
suppressor genes) incur an increased risk of breast cancer (BC) and/or OC and, to a lesser 
extent, other cancers [2,3]. The general population’s lifetime risk of developing OC is 1.5% 
[4], compared with 40–60% and 11–30% for women with BRCA1 and BRCA2 germline 
mutations, respectively [5]. Approximately 6–25% of OC patients have a BRCA1/BRCA2 
germline mutation [4], and a further 5–11% have a somatic mutation [5,6].  
Identification of BRCA-mutated OC patients is important to identify those at further cancer 
risk, at-risk family members and for individual treatment decisions, as germline/somatic 
BRCA-mutated OCs are associated with improved response to platinum-based 
chemotherapy (OC standard-of-care) and long-term prognosis than non-BRCA-associated 
OCs [2,7]. Furthermore, in 2015, the first poly adenosine diphosphate [ADP] ribose 
polymerase inhibitor (PARPi; olaparib [Lynparza™]) was licensed in Europe for BRCA-
mutated (germline/somatic) high-grade serous OC (HGSO) treatment [8]. Thus, BRCA 
genetic analysis is now also important to identify PARPi therapy candidates. 
Despite up to 25% of OCs harbouring a BRCA1/2 germline mutation [4], >40% of mutation 
carriers have no known family history of BC/OC [4,10]. Traditionally, BRCA genetic testing 
referral was based on family history, thus likely to miss many OC BRCA carriers. In light of 
the now recognised high incidence of BRCA mutations in OCs, recently updated guidelines 
have extended testing beyond those with a family history. For example, the European 
Society of Medical Oncology (ESMO) BRCA testing guidelines, 2011 update, recommend 
testing based on family history and estimated mutation risk [11], whereas international 
guidelines by the National Comprehensive Cancer Network [12], 2015 update, recommend 
BRCA testing in all invasive OC patients and the Society of Gynaecological Oncology 
guidelines [13], 2014 update, recommend testing all patients with epithelial ovarian, tubal 
and peritoneal cancers (Table 1). OC BRCA testing guidelines have recently been updated 
in many European countries, representing a shift away from family-history-based testing 
towards OC histology based recommendations, reflecting the need to identify patients for 
treatment decisions and patient’s lack of accurate family history. The published/open-access 
guidelines available for BRCA testing in OC patients are summarised in Table 1 [11–25]. 
The referral criteria differ between these published guidelines due, mostly, to guideline 
publication timing and understanding OC patients’ mutation risk at that time, along with 
considered local practicalities of excluding/including minority patient groups with a low 
mutational risk. Furthermore, many institutions have established practices not stipulated in 
their national guidelines; for example, the Royal Marsden Hospital (UK) and the Leuven 
Cancer institute (Belgium, EU) test all ovarian (fallopian tube and primary peritoneal), non-
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mucinous cancer patients for germline BRCA mutations. The aim of this manuscript is to 
review the existing data/guidelines and provide an updated opinion on recommendations 
and considerations for the referral of OC patients for BRCA genetic testing. 
 
Referral criteria for BRCA testing in OC patients 
In unselected population studies, BRCA mutations are most frequently associated with high-
grade serous OC (HGSOC) (17%) and to a lesser extent with low-grade serous carcinoma 
[26]; 1–13% of other homologies also harbour BRCA mutations (Table 2; [8, 26–30]). Based 
on this evidence, and in line with recently updated guidance, it is recommend that OC 
patients with invasive epithelial OC (excluding borderline and mucinous), including fallopian 
tube and peritoneal cancers, irrespective of age, are considered for referred for BRCA 
genetic testing; non-epithelial cancers that should also be excluded include germ cell and 
sex cord–stromal tumours.  
The decision to exclude pure borderline and mucinous OCs is based on the lack of 
association between BRCA mutations and these histologies (Table 2). However, some 
institutions may choose to include mucinous tumours because BRCA mutations have been 
reported in mucinous tumours [31], and including the relatively few patients with this 
histology would not significantly impact upon the testing services burden. 
Retrospective testing is also recommended for patients in long-term follow-up because of 
family member implications and BC risk in disease free germline BRCA-mutated OC 
patients. Patients with stage 1 OC often receive care under a general gynaecologist and 
may not be seen by a medical or gynaecological oncologist. Therefore, it is important to alert 
all clinicians treating OC of the importance of identifying patients meeting current BRCA 
testing referral criteria. Ideally, pathologists could include a statement for clinicians to be 
aware that patients with invasive non-mucinous/borderline epithelial OC may harbour a 
germline BRCA mutation in OC-related pathology reports, although this may have regulatory 
implications in some countries due to third party sharing of genetic information, e.g. 
insurance companies. 
 
BRCA genetic testing recommendations 
Ideally, to eliminate follow-up loss and for treatment implications previously stated, patients 
should be offered genetic testing at diagnosis, as this information is helpful for patient 
management. However, if this does not occur, patients can be referred at any stage during 
the patient pathway; Figure 1 is a proposed algorithm, devised during a consensus meeting 
held in Europe with European experts. 
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BRCA analysis differs from other genetic tests for cancer treatment decisions, e.g. RAS  or 
epidermal growth factor receptor, because an identified OC BRCA1/2 pathogenic mutation is 
likely to be a somatic event in ~15–20% of cases and a germline event in the remaining 80–
85% [8]. Thus, patients need to be informed about the implications of the result, both for 
themselves and family members. Genetic counselling is a requirement (by law in many 
countries) prior to patients undergoing testing. Traditionally, this counselling has been 
delivered by trained geneticists/genetic counsellors at specialised genetic/family cancer 
centres. However, due to the increasing demand for BRCA testing services, new models for 
delivery of genetic counselling have been developed and their use has increased in recent 
years. For example, in the UK, The Royal Marsden NHS Foundation Trust/Institute of 
Cancer Research has developed a system to support the implementation of BRCA testing in 
routine oncology appointments. In this Mainstreaming Cancer Genetics (MCG) programme, 
members of the oncology team undergo online training to enable them to deliver initial 
genetic counselling to women for whom BRCA testing is recommended. All patients have the 
option of seeing a trained geneticist/genetic counsellor prior to deciding on whether to 
proceed with testing and are followed up by a trained geneticist/genetic counsellor if found to 
harbour a mutation [10]. As of 2015, 300 women had gone through this MCG programme; a 
survey (n=105) found 99% were happy with their decision to undertake the test and 97% 
were satisfied to have had the test organised via the oncology department. As part of this 
initiative, gynae-oncology clinical nurse specialists, as well as doctors have counselled and 
consented patients for germline BRCA testing; nurses consented 36% of patients in 
oncology clinics and thus far, feedback has been positive [32]. This programme is being 
further evaluated in a larger study (ENGAGE study), which is assessing this model at 30 
sites in the USA, Italy and Spain. ENGAGE aims to include ~400 patients with epithelial 
ovarian, fallopian tube or primary peritoneal cancer 
(https://clinicaltrials.gov/ct2/show/NCT02406235). Preliminary results of the European arm 
are anticipated towards the end of 2016. Details and resources for the MCG programme are 
freely available at: https://mcgprogramme.com/brcatesting/. Further information on different 
methods to deliver genetic counselling can be found on the European Society of 
Gynaecological Oncology eAcademy platform http://eacademy.esgo.org/esgo/. Pre-test 
telephone interviews with genetic counsellors have also been evaluated in patients referred 
for BRCA testing. In a randomised non-inferiority trial, telephone counselling was found to be 
non-inferior to in-person counselling for knowledge, perceived stress and patient satisfaction 
[33]. Following receipt of genetic counselling, patients must also provide their written 
informed consent prior to testing. 
Sample type (blood/tumour tissue) 
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Olaparib is licensed for OC patients with either germline or somatic BRCA mutations. The 
limited data available support the hypothesis that somatic BRCA-mutated OCs respond 
equally to PARPi as germline-mutated [7,8], although further studies are needed to confirm 
this. Methods also need to be validated for the identification of BRCA mutations in fixed 
tissue samples; such primary surgery samples are the most readily available to utilise for 
testing. There is some evidence supporting the stability of both somatic and germline BRCA 
mutations between samples taken during initial surgery and following relapse [34]; however, 
further studies are required, and mutations may not always remain stable during disease 
progression. For these reasons, for the time being, germline testing of a blood/saliva sample 
is recommended in the first instance, followed by consideration to test tumour tissue upon 
obtaining a negative result (Table 3). However, ultimately, it may be both logical and cost-
effective to test OC tumour samples for BRCA mutations first, and then, if positive, go on to 
confirm if mutations are germline or somatic by testing a blood/saliva sample because of the 
cost implications of testing all patients for germline mutations and then repeat testing all who 
obtain a negative result, in order to identify the further 5–7% of patients who may potentially 
benefit from PARPi therapy. In addition, in the near future, it is expected that not only 
patients with somatic BRCA mutations but also patients with a proven tumour homologous 
recombination deficiency might be candidates for PARPis [35].  
Turnaround times / technical  
Ideally, results of BRCA genetic testing should be available within 4–8 weeks, if required for 
treatment decisions. Further technical recommendations for BRCA testing are outlined in 
Table 3.  
 
Conclusions 
Worldwide studies have highlighted that BRCA mutations among OC patients are more 
frequent than previously thought. This together with the licensing of the first PARPi therapy 
for BRCA-associated OC (with further drugs in this class likely to be licensed soon) has led 
to a change in the rationale for BRCA testing criteria. Referral criteria, previously based on 
family cancer history and designed to identify those at risk of future cancers, are being 
changed to identify those who may benefit from treatment and those at risk who lack a 
known family history and who may benefit from future preventative strategies.  
BRCA testing differs from other tumour treatment decision genetic tests because OC BRCA 
mutations are likely to be germline, with individual and family member implications beyond 
current treatment. Thus, information, genetic counselling and written informed consent are 
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required prior to BRCA testing. Although originally initiated to reduce waiting times and save 
costs, initial genetic counselling by trained medical staff, in close collaboration with medical 
geneticists, is now being adopted by many institutions because it has been found to work 
well and to be at least as well accepted by patients as classical genetic counselling. 
The published guidance on BRCA testing in OC patients differs in various recommendations 
because of differences in understanding at the time of publishing, highlighting that ideally 
guidelines should be re-evaluated, and updated if necessary, at least every 2 years. 
Following a review of newly updated guidance and up-to-date evidence, the following is 
recommended: all OC patients with invasive epithelial OC (excluding borderline and 
mucinous), including fallopian tube and peritoneal cancers, should be considered for referred 
for BRCA genetic testing, irrespective of age; genetic testing should ideally be offered at 
diagnosis, although patients can be referred at any stage; retrospective testing should be 
offered to long-term follow-up patients because of family member implications and individual 
future BC risk; and germline BRCA testing of a blood/saliva sample should initially be 
conducted and, if negative, a tumour tissue sample tested to identify non-germline BRCA 
PARPi therapy candidates (Figure 1, Table 3).   
OC genetics understanding is evolving: genes other than BRCA1 and BRCA2 have been 
associated with OC development, and loss of other genes involved in homologous DNA 
recombination is thought to potentially confer PARPi response [5,26]. Furthermore, genomic 
scar tests, which identify signs of homologous recombination deficiency, are being evaluated 
to identify further PARPi-responsive patients [5]. However, scar assays do not preclude the 
requirement for BRCA testing because of the need to identify individuals and family 
members at risk of future cancers. In the future, studies exploring the effect of PARPi 
treatment on somatic BRCA mutations will also be of interest.  
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Table 1. Summary of international and individual published guidance on BRCA mutation testing of OC patients  
  Criterial for referral for testing Testing recommendations 
 
Year 
published 
Based on family 
history 
Based on patient 
characteristics 
Based on risk Based on  
histology 
Type of sample  Timing of testing Turnaround 
time of tests 
ESMO [11] 
 2011 
 
≥3 BCs and/or OCs in 
the family (at least 1 
<50 yrs) 
BC and OC in the 
same patient 
BC and OC in the 
same patient 
10–20% chance of 
finding a mutation 
(predictive models) 
– – – – 
NCCN [12] 2015 
 
≥1 invasive primary 
OC 
Invasive OC No 
recommendations 
- – – – 
SGO [13] 
2014 
 
≥1 invasive primary 
OC 
Epithelial ovarian, 
tubal and peritoneal 
cancers 
No 
recommendations 
– – – – 
Austria [14] 2015 1 BC <35 yrs 
2 BCs ≥1  
 <50 yrs 
3 BCs <60 yrs 
1 BC + 1 OC 
2 OCs 
1 male BC 
Epithelial OC Not defined TNBC <60 yrs Blood (quality 
control testing of 
tumour) 
At diagnosis 
At recurrence 
Not defined 
Belgium [15] 2015 NA to OC patients NA to OC patients No 
recommendations 
All HGSOC First blood and if 
negative tumour 
During 1st-line 
therapy 
Institution 
dependent; use 
fast track for 
treatment 
decisions 
Czech Republic 
[16] 
2015 ≥3 BCs any age 
≥2 BCs 1≤ 50 yrs or 
2 ≤60 yrs 
Bilateral BC 
BC ≤50 yrs 
BC and pancreatic 
cancer 
Male BC 
 
– All patients with 
epithelial ovarian, 
fallopian tube, or 
primary 
peritoneal cancer 
regardless of the 
age at diagnosis 
TNBC ≤60 yrs 
– – Within 3 months 
for therapy 
decisions 
Finland [17] 2012 ≥1 BC OC with 1 close 
relative with OC 
OC and BC 
– – – – – 
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France [18] 
 
  
2016 Low-grade OC, tubal 
or primary carcinoma 
any age + 1st degree 
relative (or 2nd degree 
if male 1st degree) 
with BC or OC 
regardless age at 
diagnosis 
OC, tubal or primary 
peritoneal carcinoma, 
any age, regardless 
of family history if HG 
(serous, 
endometrioid, clear 
cell, carcinosarcoma) 
or if affected with BC 
-  OC, tubal or 
primary 
peritoneal 
carcinoma, any 
age if HG 
(serous, 
endometrioid, 
clear cell, 
carcinosarcoma)  
Blood in 1st-line 
Blood & tumour 
in sensitive 
relapsed 
patients 
At diagnosis 4–6 months in 
1st-line 
4–8 weeks for 
sensitive 
relapsed 
patients 
Germany [19] 2013 3 BCs 
2 BCs 1 <51 yrs 
1 BC and 1 OC 
2 OCs 
1 male BC 
BC and OC 
Bilateral BC 
BC <36 yrs 
Risk based on 
family history 
HGSOC (for 
therapy 
decisions) 
Blood or tumour, 
or both 
At diagnosis or if 
risk factors present 
10–14 days 
Italy [20] 2015 Genetic family history 
(old guidelines) 
BC and OC 
OC <45 yrs 
>10% risk All non-
mucinous, non-
borderline 
Blood or tumour At diagnosis Not indicated 
Netherlands [21] 2015  All epithelial OC 
(including fallopian) 
– All excluding 
borderline 
No 
recommendation  
No 
recommendation  
No 
recommendation 
Portugal [22] 2013 – BC and OC (other 
multi-multiple 
tumours) 
≥10% risk 
(BRCAPRO) 
HGSOC Blood At diagnosis/ 
during primary 
treatment 
1–6 months 
Spain [23] 2016 1 BC and 1 OC 
2 OC 
OC <40 yrs 
  Epithelial OC 
(fallopian cancer 
or primary 
peritoneal 
cancer), HG for 
the histologic 
subtypes 
HGSOC, clear 
cell, 
endometrioid, 
undifferentiated 
and 
carcinosarcoma 
Blood, if 
negative 
perform tumour 
testing for 
therapeutic 
purposes 
At diagnosis or 
time of relapse in 
platinum-sensitive 
patients 
Within  
4 months 
Scotland [24] 2013 Family history of BC 
and/or OC, colon 
cancer 
– >10% risk Non-mucinous 
OC, fallopian 
tube cancer 
– – – 
14 
 
UK [25]  2015 4 BCs 
3 BCs <60 yrs 
2 BCs <50 yrs 
OC and BC <50 yrs 
OC and 2 BCs  
<60 yrs 
2 OCs 
Bilateral BC <50 yrs 
Male BC and  
≥1 BCs <60 yrs 
– >10% risk – Blood – – 
BC, breast cancer; OC, ovarian cancer; HGSOC, high-grade serous ovarian cancer; HG, high grade; TNBC, triple-negative breast cancer 
*Criteria likely to be included in 2016 update of guidelines  
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Table 2. Percentage of ovarian cancer patients, by histology, with germline BRCA1 or BRCA2 mutations in different published 
studies of populations with unknown BRCA1/2 status 
Study  Serous % Mucinous % Endometrioid % Clear cell % Undifferentiated % Other/unspecified % 
Alsop 2012 [9] 
(N=1001) 
16.6 0 8.4 6.3 – 8.2 
Jacobi 2007 [27] 
(N=85) 
10.8 0 0 0 0 0 
Malander 2004 [28] 
(N=161) 
7.6 0 13.0 12.5 – 0 
Norquist 2015 [26] 
(N=1915) 
16 (HGS)  
5.6 (LGS) 
0 8.8 6.9 – 53.5 
Soegaard 2008 [29] 
(N=445) 
5.5 0 5.4 9.1 12.5 10.0 
Risch 2001 [30] 
(N=649) 
16.4 0 4.3 0 – 0 
HGS, high-grade serous; LGS, low-grade serous 
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Table 3. Summary of BRCA testing recommendations for OC patients 
Criteria Recommendation 
Timing of testing At diagnosis 
Or if not undertaken at diagnosis at any stage during the patient pathway 
Retrospective testing should be offered to patients in long-term follow-up because of the implications for other 
family members and the future risk of breast cancer in the individual patient 
Patients to refer for testing All OC patients with invasive epithelial OC (excluding borderline and mucinous), including fallopian tube and 
peritoneal cancers, irrespective of age 
Genetic counselling requirements Some form of genetic counselling together with written informed consent are required prior to patients undergoing 
testing 
Sample type Germline testing of a blood/saliva sample for BRCA mutations should be conducted in the first instance, followed 
by testing of tumour tissue if a negative result is obtained (to identify those suitable for PARPi therapy who are not 
germline carriers of a BRCA mutation) 
Technical  Full gene analysis, not just hot spots, should be undertaken, including rearrangements and deletions 
Certified labs should be used for analyses with quality control in place (European Molecular Genetics Quality 
Network or equivalent) 
Next-generation sequencing should be used for tumour testing 
Turnaround times  4–8 weeks 
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Figure 1. The BRCA genetic testing patient journey in ovarian cancer  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VUS, variants of uncertain significance 
